for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hansoh Pharmaceutical Group Co Ltd

3692.HK

Latest Trade

25.20HKD

Change

0.10(+0.40%)

Volume

94,000

Today's Range

25.00

 - 

25.35

52 Week Range

16.12

 - 

29.55

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
25.10
Open
25.00
Volume
94,000
3M AVG Volume
86.53
Today's High
25.35
Today's Low
25.00
52 Week High
29.55
52 Week Low
16.12
Shares Out (MIL)
5,788.61
Market Cap (MIL)
145,294.10
Forward P/E
47.90
Dividend (Yield %)
--

Latest Developments

More

Hansoh Pharmaceutical Group Gets Drug Registration Approval For Its "Tanneng" Product

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hansoh Pharmaceutical Group Co Ltd

HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED is a China-based investment holding company principally involved in the the research and development, production and sale of pharmaceutical products. The Company’s main products include Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xinmei, Zetan, Mailingda, Hengjie, Hengsen, Fulaidi and Ruibote, among others. The Company’s products are mainly used for central nervous system disease, oncology, anti-infection, diabetes, digestive tract and cardiovascular treatment. The Company distributes its products in domestic market.

Industry

Biotechnology & Drugs

Contact Info

9 Dongjin Road

Economic & Technical Development Zone

http://www.hspharm.com/

Key Stats

2.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2019(E)

9.7K
EPS (CNY)

2019(E)

0.466
Price To Earnings (TTM)
53.89
Price To Sales (TTM)
15.24
Price To Book (MRQ)
10.47
Price To Cash Flow (TTM)
55.70
Total Debt To Equity (MRQ)
0.08
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Hold the beers: Budweiser APAC IPO hit by investor push-back

Scepticism over AB InBev's high valuations doomed Budweiser APAC's IPO of up to $9.8 billion - poised to be the world's biggest this year - investors and bankers said, putting would-be floats on notice that careful pricing remains key to success.

Hold the beers: Budweiser APAC IPO fail shows valuations face investor push-back

By Julie Zhu, Joshua Franklin, Abhinav Ramnarayan and Philip Blenkinsop

Asia bankers bet on Alibaba, follow-on fundraising amid trade gloom

Asia's army of equity capital bankers are betting on a stream of listed companies seeking fresh funds, including Alibaba's plans for an up to $20 billion Hong Kong share sale, as trade tensions continue to weigh on the big business of taking firms public.

Goldman Sachs hires Asia healthcare banker from Morgan Stanley: sources

Goldman Sachs has hired Samuel Thong from Morgan Stanley as the chairman of the healthcare group in the bank's Asia excluding-Japan investment banking division, people with knowledge of the move said.

BREAKINGVIEWS - China’s pharma shake-up wins healthy endorsement

China's pharma shake-up has won a healthy endorsement. Drugmaker Hansoh Pharmaceutical <3692.HK> will go public this week after raising funds at a $10.3 billion valuation in its Hong Kong initial public offering. That suggests that Beijing’s radical price reforms will produce...

UPDATE 1-Hansoh Pharma raises $1 bln in HK IPO priced at top of range-sources

* Shares were being sold in indicative band of HK$13.06-HK$14.26

Hansoh Pharma raises $1 billion in HK IPO priced at top of range: sources

Drugmaker Hansoh Pharmaceutical Group on Wednesday priced its Hong Kong initial public offering at the top end of its targeted range, two people with direct knowledge of the matter said, raising roughly $1 billion.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up